Amgen Stock Rises Amid Regulatory Developments

Amgen stock rose by 1.1 percent to close at $381.96 on Nasdaq on September 14, 2026.

This gain came despite a broader market decline, with the S&P 500 falling 0.5 percent and the Nasdaq Composite dropping 0.6 percent that day.

The company's stock price was influenced by recent regulatory developments and sector pressure in healthcare.

Amgen's Imdelltra bispecific T-cell engager therapy received FDA approval for a reduced monitoring time, simplifying the treatment protocol and potentially influencing adoption trends in oncology.